Compass Pathways Announces New Employee Inducement Grants

Biotech firm grants equity awards to newly hired non-executive employees under Nasdaq listing rule.

Apr. 8, 2026 at 6:19am

Got story updates? Submit your updates here. ›

A minimalist, photorealistic studio still life featuring a stack of polished metal stock tickers, a glass beaker filled with a vibrant blue liquid, and a sleek silver syringe, all arranged elegantly on a clean, monochromatic background, conceptually representing the intersection of biotechnology, finance, and mental health innovation.Compass Pathways' new equity grants aim to fuel its mission of pioneering novel mental health treatments through strategic talent acquisition.NYC Today

Compass Pathways plc, a biotechnology company focused on mental health treatments, announced that it has granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The awards consisted of options to purchase an aggregate of 117,445 shares and restricted share units or nominal cost options covering an aggregate of 55,875 shares.

Why it matters

The equity grants are intended to serve as a material inducement for the new hires to join the company, which is pioneering a new approach to treating mental health conditions with its investigational COMP360 synthetic psilocybin treatment. The awards were approved by Compass's Compensation and Leadership Development Committee in accordance with Nasdaq listing rules.

The details

The options have an exercise price per share of $5.62, the closing price of the company's American Depositary Shares on the Nasdaq Global Select Market on the grant date. The options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following three years. The restricted share units and nominal cost options will vest in four equal annual installments.

  • The equity awards were granted on April 1, 2026.
  • The options have an exercise price per share equal to $5.62, the closing price on the grant date.

The players

Compass Pathways plc

A biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, including the development of its investigational COMP360 synthetic psilocybin treatment.

Compass Pathways plc 2026 Inducement Plan

The equity award plan under which the new hires were granted options and restricted share units as a material inducement to their employment.

Got photos? Submit your photos here. ›

The takeaway

The equity grants highlight Compass Pathways' efforts to attract top talent as it advances its innovative mental health treatments, including its COMP360 psilocybin therapy which has received Breakthrough Therapy designation from the FDA.